Fludarabine
- Generic Name
- Fludarabine
- Brand Names
- Fludara
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12FN5O4
- CAS Number
- 21679-14-1
- Unique Ingredient Identifier
- P2K93U8740
- Background
Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
- Indication
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
- Associated Conditions
- B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- -
Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia
- Interventions
- Drug: IsatuximabDrug: Dexamethasone or equivalentDrug: FludarabineDrug: CytarabineDrug: Liposomal daunorubicinDrug: Daunorubicin (nonliposomal)Drug: IdarubicinDrug: Filgrastim or equivalentDrug: MitoxantroneDrug: DoxorubicinDrug: VincristineDrug: Pegaspargase (PEG) AsparaginaseDrug: CyclophosphamideDrug: EtoposideDrug: MethotrexateDrug: L - AsparginaseDrug: HydroxyureaDrug: L - Asparaginase (Erwinase)
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 67
- Registration Number
- NCT03860844
- Locations
- 🇺🇸
Children's Medical Center of Dallas-Site Number:8400002, Dallas, Texas, United States
🇲🇽Investigational Site Number :4840001, Monterrey, Nuevo León, Mexico
🇧🇷Investigational Site Number :0760007, Porto Alegre, Rio Grande Do Sul, Brazil
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
- Conditions
- Acute Lymphoblastic LeukemiaB Acute Lymphoblastic LeukemiaLymphocytic NeoplasmLymphoma
- Interventions
- Procedure: Allogeneic Bone Marrow TransplantationBiological: Filgrastim-sndzDrug: BendamustineDrug: FludarabineDrug: MelphalanBiological: Inotuzumab OzogamicinProcedure: Peripheral Blood Stem Cell TransplantationBiological: RituximabDrug: Tacrolimus
- First Posted Date
- 2019-02-27
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT03856216
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
- Conditions
- Acute Myeloid Leukemia in RemissionMyelodysplastic SyndromesChronic Myeloid Leukemia in RemissionMyeloproliferative SyndromeMyeloproliferative DisorderAcute Lymphoid Leukemia in RemissionMultiple MyelomaChronic Lymphoid LeukemiaNon Hodgkin LymphomaHodgkin Lymphoma
- Interventions
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- University of Liege
- Target Recruit Count
- 114
- Registration Number
- NCT03852407
- Locations
- 🇧🇪
CHU UCL Namur Godinne, Yvoir, Belgium
🇧🇪UZ Gent, Gent, Belgium
🇧🇪UCL St Luc, Brussels, Belgium
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
- Conditions
- Cervical CancerAdvanced Solid TumorsEGFR Positive Solid TumorHepatocellular CarcinomaRenal Cell CarcinomaNSCLCUrothelial CarcinomaColorectal CancerSmall Cell Lung CancerMelanoma
- Interventions
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 37
- Registration Number
- NCT03841110
- Locations
- 🇺🇸
Hackensack University Medical Center/John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA
- Conditions
- Engraft FailureAplastic AnemiaStem Cell Transplant Complications
- Interventions
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 55
- Registration Number
- NCT03821987
- Locations
- 🇨🇳
Peking University Institute of Hematology,People's hospital Peking University, Beijing, Beijing, China
A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Drug: FludarabineDrug: AlemtuzumabDrug: MelphalanDrug: CyclophosphamideDrug: MesnaRadiation: Total Body Irradiation (8Gy)
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 242
- Registration Number
- NCT03821610
- Locations
- 🇬🇧
Cardiff and Vale University Health Board, Cardiff, United Kingdom
🇬🇧The Clatterbridge Cancer Centre Nhs Foundation Trust, Liverpool, United Kingdom
🇬🇧University Hospitals of Leicester Nhs Trust, Leicester, United Kingdom
The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- Shanghai 6th People's Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT03814447
- Locations
- 🇨🇳
Shanghai 6th People's Hospital, Shanghai, Shanghai, China
Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Conditions
- Recurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeRefractory Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT03813147
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 20
- Registration Number
- NCT03799913
- Locations
- 🇨🇳
The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: QuizartinibDrug: FludarabineDrug: CytarabineDrug: Intrathecal (IT) triple chemotherapy prophylaxisDrug: Etoposide
- First Posted Date
- 2019-01-04
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 65
- Registration Number
- NCT03793478
- Locations
- 🇺🇸
Loma Linda University Cancer Center, Loma Linda, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.